--- title: "Buy Rating Reiterated as Auvelity’s Expanded Alzheimer’s Opportunity Drives Upgraded $276 Price Target" type: "News" locale: "en" url: "https://longbridge.com/en/news/285176899.md" description: "Jason Gerberry from Bank of America Securities reiterated a Buy rating on Axsome Therapeutics, raising the price target to $276. He cites Auvelity’s expanding commercial opportunity in Alzheimer’s disease agitation and management’s $8 billion peak sales ambition as key factors. The upcoming launch and a strengthened sales force are expected to drive growth. Needham also assigned a Buy rating with a $267 target. Gerberry is a 5-star analyst with an 18.9% average return and a 61.32% success rate." datetime: "2026-05-05T08:55:52.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/285176899.md) - [en](https://longbridge.com/en/news/285176899.md) - [zh-HK](https://longbridge.com/zh-HK/news/285176899.md) --- # Buy Rating Reiterated as Auvelity’s Expanded Alzheimer’s Opportunity Drives Upgraded $276 Price Target In a report released yesterday, Jason Gerberry from Bank of America Securities reiterated a Buy rating on Axsome Therapeutics, with a price target of $276.00. ### Claim 55% Off TipRanks - Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions - Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks Jason Gerberry has given his Buy rating due to a combination of factors related to Auvelity’s expanding commercial opportunity and the stock’s valuation. He highlights that management’s new $8 billion peak sales ambition for Auvelity, supported by the recent approval in Alzheimer’s disease agitation and a favorable label, is not fully reflected in the current share price, even versus more conservative consensus peak estimates. He also points to the upcoming Alzheimer’s agitation launch, the enlarged 630-person sales force promoting both depression and Alzheimer’s indications, and the proven benefits of indication stacking in CNS drugs as key growth drivers that can unlock substantial upside. Additionally, he notes robust early traction in major depressive disorder, rising peak MDD sales assumptions, and a strengthened longer-term pipeline, all of which underpin his reiterated Buy rating and increased price objective of $276 per share. According to TipRanks, Gerberry is a 5-star analyst with an average return of 18.9% and a 61.32% success rate. Gerberry covers the Healthcare sector, focusing on stocks such as Ionis Pharmaceuticals, Alkermes, and BioMarin Pharmaceutical. In another report released yesterday, Needham also assigned a Buy rating to the stock with a $267.00 price target. ### Related Stocks - [AXSM.US](https://longbridge.com/en/quote/AXSM.US.md) - [BAC.US](https://longbridge.com/en/quote/BAC.US.md) - [IONS.US](https://longbridge.com/en/quote/IONS.US.md) - [ALKS.US](https://longbridge.com/en/quote/ALKS.US.md) - [BMRN.US](https://longbridge.com/en/quote/BMRN.US.md) - [BAC-Q.US](https://longbridge.com/en/quote/BAC-Q.US.md) - [BML-L.US](https://longbridge.com/en/quote/BML-L.US.md) - [BAC-L.US](https://longbridge.com/en/quote/BAC-L.US.md) - [BAC-K.US](https://longbridge.com/en/quote/BAC-K.US.md) - [BML-H.US](https://longbridge.com/en/quote/BML-H.US.md) - [BAC-N.US](https://longbridge.com/en/quote/BAC-N.US.md) - [BAC-E.US](https://longbridge.com/en/quote/BAC-E.US.md) - [MER-K.US](https://longbridge.com/en/quote/MER-K.US.md) - [BAC-O.US](https://longbridge.com/en/quote/BAC-O.US.md) - [BML-G.US](https://longbridge.com/en/quote/BML-G.US.md) - [BAC-M.US](https://longbridge.com/en/quote/BAC-M.US.md) - [BAC-B.US](https://longbridge.com/en/quote/BAC-B.US.md) - [BML-J.US](https://longbridge.com/en/quote/BML-J.US.md) - [BAC-S.US](https://longbridge.com/en/quote/BAC-S.US.md) - [BAC-P.US](https://longbridge.com/en/quote/BAC-P.US.md) - [8648.JP](https://longbridge.com/en/quote/8648.JP.md) ## Related News & Research - [Axsome Therapeutics Bets on AUVELITY Expansion With June Alzheimer’s Agitation Launch](https://longbridge.com/en/news/286164148.md) - [Axsome’s AUVELITY Alzheimer’s Approval Sparks Valuation And Growth Questions](https://longbridge.com/en/news/286077483.md) - [ACADIA Pharmaceuticals Spotlights Alzheimer’s Psychosis Pipeline, NUPLAZID and DAYBUE Growth](https://longbridge.com/en/news/286928593.md) - [13:16 ETCaringKind's Inaugural Hope Blooms Event Raises Close to $200,000 to Expand Alzheimer's and Dementia Care in Connecticut](https://longbridge.com/en/news/286948547.md) - [Axsome Therapeutics Wins FDA Nod for Auvelity in Alzheimer’s Agitation, Launch Set for June](https://longbridge.com/en/news/284906140.md)